D-0681-2022 Class II Terminated

Recalled by Teligent Pharma, Inc. — Buena, NJ

FDA drug recall D-0681-2022 was initiated by Teligent Pharma, Inc. on Mar 15, 2022 and is designated Class II. Reason for recall: cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program. The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 24,304 bottles.

Recall Details

Product Type
Drugs
Report Date
Mar 30, 2022
Initiation Date
Mar 15, 2022
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
24,304 bottles

Product Description

Diflorasone Diacetate Ointment USP, 0.05%, Net Wt 60 g tubes, Rx only, Manufactured for: SOLA Pharmaceuticals, LLC Baton Rouge, LA 70809, NDC 70512-031-60.

Reason for Recall

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Distribution Pattern

Nationwide in the USA and Puerto Rico

Code Information

Batch: 15800, Exp. 7/31/2022; 15876, 15904, 15917, 15922, Exp. 8/31/2022; 16202, 16203, Exp. 11/30/2022.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0681-2022
openFDA file date
Oct 23, 2026
Loaded by RegDataLab
Oct 26, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.